SecBot SecBot
PRESS-RELEASE ·Filed Mar 23, 2026

APGE

Apogee Therapeutics
BULLISH
Impact 8/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Traders should monitor the upcoming APEX Part B 16-week induction data in 2Q 2026, which will be critical for confirming efficacy and supporting Phase 3 initiation. Positive results could further drive upside given the high unmet need for infrequently dosed AD therapies.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$79.24
T+0 close · Mar 23, 2026 · via day close
Latest settled
+11.60%
T+60 · $88.43
Vs SPY
−1.46%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 23 $79.24entry
  2. T+1 · 8mo ago −7.87%α −7.52% · $73.00
  3. T+5 · 8mo ago −0.66%α +2.91% · $78.72
  4. T+20 · 7mo ago +14.66%α +7.24% · $90.86
  5. T+60 · 5mo ago +11.60%α −1.46% · $88.43
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Apogee Therapeutics announced positive 52-week maintenance data from Part A of its Phase 2 APEX trial for zumilokibart (APG777), an anti-IL-13 antibody in moderate-to-severe atopic dermatitis. The drug showed durable and deepening responses with every 3- and 6-month dosing, supporting its potential as a best-in-class therapy with infrequent dosing. Phase 3 trials are expected to begin in the second half of 2026, with a potential 2029 commercial launch.

Key Facts

  • Zumilokibart demonstrated 75% and 85% maintenance of EASI-75 response at 52 weeks with every 3- and 6-month dosing, respectively.
  • vIGA 0/1 response was maintained in 86% (3-month) and 78% (6-month) of Week 16 responders.
  • Deepening of response observed across all lesional and itch endpoints in the full treated population, not just initial responders.
  • Drug was well tolerated with a safety profile consistent with class; most common TEAEs: noninfective conjunctivitis, URTI, nasopharyngitis.
  • Phase 3 trials expected to initiate in 2H 2026, with potential commercial launch in 2029.

Financial Impact

No direct financial figures reported, but successful Phase 2 data de-risks development and increases probability of regulatory approval and commercial success.

valuationrevenue potentialpipeline value

Risk Factors

  • Phase 3 trials have not yet started; clinical success in Phase 2 does not guarantee Phase 3 outcomes.
  • Competition from existing and emerging IL-13/IL-4 inhibitors (e.g., dupilumab, tralokinumab) with established market presence.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3260201

Track record

31 reports on APGE

Performance horizon

8 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 11 of 12 went positive at some point.

Filters
  1. Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
  2. Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
  3. Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
  4. Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
  5. Aug 10, 202614w ago 8-K Bullish 8/10 No price data
  6. Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
  7. Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
  8. Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
  9. Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
  10. Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
Showing 10 of 31

US Market Status

Market Closed · Opens Wed (11h 22m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 23, 2026